Federated Hermes
AMRX icon

Federated Hermes’s Amneal Pharmaceuticals AMRX Stock Holding History

Federated Hermes’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.5K Buy
3,092
+387
+14% +$5.3K ﹤0.01% 1698
2026
Q1 		$33.6K Buy
2,705
+408
+18% +$5.48K ﹤0.01% 1724
2025
Q4 		$28.9K Buy
2,297
+2,168
+1,681% +$24.8K ﹤0.01% 1708
2025
Q3 		$1.29K Buy
129
+48
+59% +$431 ﹤0.01% 2060
2025
Q2 		$655 Sell
81
-272,990
-100% -$2.06M ﹤0.01% 2026
2025
Q1 		$2.29M Buy
273,071
+1,237
+0.5% +$10.3K ﹤0.01% 907
2024
Q4 		$2.15M Buy
271,834
+5,849
+2% +$49.1K ﹤0.01% 914
2024
Q3 		$2.21M Buy
265,985
+451
+0.2% +$3.53K ﹤0.01% 909
2024
Q2 		$1.69M Sell
265,534
-6,003
-2% -$38.1K ﹤0.01% 963
2024
Q1 		$1.65M Buy
271,537
+193,363
+247% +$1.09M ﹤0.01% 991
2023
Q4 		$475K Sell
78,174
-85
-0.1% -$379 ﹤0.01% 1355
2023
Q3 		$330K Buy
+78,259
New +$292K ﹤0.01% 1443
2022
Q3 		– Sell
-7,535
Closed -$24K – 2141
2022
Q2 		$24K Sell
7,535
-7,823
-51% -$28.3K ﹤0.01% 1746
2022
Q1 		$64K Buy
15,358
+19
+0.1% +$84 ﹤0.01% 1708
2021
Q4 		$73K Sell
15,339
-17,365
-53% -$86.6K ﹤0.01% 1750
2021
Q3 		$175K Buy
32,704
+5,122
+19% +$25.8K ﹤0.01% 1685
2021
Q2 		$141K Sell
27,582
-4,897
-15% -$27.8K ﹤0.01% 1736
2021
Q1 		$218K Sell
32,479
-92,507
-74% -$513K ﹤0.01% 1685
2020
Q4 		$572K Buy
124,986
+1,705
+1% +$7.55K ﹤0.01% 1495
2020
Q3 		$479K Buy
123,281
+10,199
+9% +$43.6K ﹤0.01% 1487
2020
Q2 		$538K Sell
113,082
-1,351,577
-92% -$5.57M ﹤0.01% 1466
2020
Q1 		$5.1M Buy
1,464,659
+1,047,868
+251% +$4.44M 0.02% 623
2019
Q4 		$2.01M Buy
416,791
+220,695
+113% +$767K ﹤0.01% 1023
2019
Q3 		$568K Buy
196,096
+195,328
+25,433% +$682K ﹤0.01% 1428
2019
Q2 		$6K Sell
768
-106
-12% -$1.08K ﹤0.01% 1948
2019
Q1 		$12K Sell
874
-78
-8% -$1.03K ﹤0.01% 1840
2018
Q4 		$13K Sell
952
-102
-10% -$1.84K ﹤0.01% 1833
2018
Q3 		$23K Sell
1,054
-175
-14% -$3.68K ﹤0.01% 1825
2018
Q2 		$20K Buy
+1,229
New +$21.6K ﹤0.01% 1796

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Federated Hermes's AMRX Position: Q2 2026 in Review

Federated Hermes increased its Amneal Pharmaceuticals (AMRX) stake by 14% in Q2 2026, buying an estimated $5.3K and bringing the position to 3,092 shares worth $53.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1698.

Federated Hermes first reported a position in AMRX in Q2 2018 and has held it in 29 quarters since. The position peaked at $5.1M in Q1 2020. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Federated Hermes held 3,092 shares of Amneal Pharmaceuticals worth $53.5K as of Q2 2026.
  • Federated Hermes bought 387 Amneal Pharmaceuticals shares in Q2 2026, an estimated $5.3K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1698 holding.
  • Federated Hermes first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
  • Federated Hermes's Amneal Pharmaceuticals position peaked at $5.1M in Q1 2020.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.